Interview with Robin Rumler, CEO, Pfizer Austria
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Company information:
BBMRI Austria is the Austrian National Node of the European biobanking research infrastructure BBMRI-ERIC.
BBMRI Austria links Austrian universities and biobanks with the goal to establish a national biobanking research infrastructure for accelerating biomedical research.
Address: Neue Stiftingtalstrasse 2/B/6, A-8010 Graz, Austria
Website: http://bbmri.at/
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed…
Just like other European countries, Austria is in the search for meaningful savings in healthcare. Austria’s increasingly price sensitive pharma market is seeing the rise of generic medicines gaining market…
Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so…
You have been General Secretary of PHARMIG since 2004 and have witnessed the market’s development over the past 8 years. What have been the most important changes since you started…
See our Cookie Privacy Policy Here
